Safdar Nasia, Maki Dennis G
Section of Infectious Diseases, Department of Medicine, University of Wisconsin Medical School, Madison, USA.
Chest. 2005 Aug;128(2):489-95. doi: 10.1378/chest.128.2.489.
Peripherally inserted central venous catheters (PICCs) are now widely used for intermediate and long-term access in current-day health care, especially in the inpatient setting, where they are increasingly supplanting conventional central venous catheters (CVCs) placed percutaneously into the internal jugular, subclavian, or femoral veins. Data on the risk of PICC-related bloodstream infection (BSI) with PICCs used in hospitalized patients are limited.
To determine the risk of PICC-related BSI in hospitalized patients.
Prospective cohort study using data from two randomized trials assessing the efficacy of chlorhexidine-impregnated sponge dressing and chlorhexidine for cutaneous antisepsis.
PICCs inserted into the antecubital vein in two randomized trials during from 1998 to 2000 were prospectively studied; most patients were in an ICU. PICC-related BSI was confirmed in each case by demonstrating concordance between isolates colonizing the PICC at the time of removal and from blood cultures by restriction-fragment DNA subtyping.
Overall, 115 patients had 251 PICCs placed. Mean duration of catheterization was 11.3 days (total, 2,832 PICC-days); 42% of the patients were in an ICU at some time, 62% had urinary catheters, and 49% had received mechanical ventilation. Six PICC-related BSIs were identified (2.4%), four with coagulase-negative staphylococcus, one with Staphylococcus aureus, and one with Klebsiella pneumoniae, a rate of 2.1 per 1,000 catheter-days.
This prospective study shows that PICCs used in high-risk hospitalized patients are associated with a rate of catheter-related BSI similar to conventional CVCs placed in the internal jugular or subclavian veins (2 to 5 per 1,000 catheter-days), much higher than with PICCs used exclusively in the outpatient setting (approximately 0.4 per 1,000 catheter-days), and higher than with cuffed and tunneled Hickman-like CVCs (approximately 1 per 1,000 catheter-days). A randomized trial of PICCs and conventional CVCs in hospitalized patients requiring central access is needed. Our data raise the question of whether the growing trend in many hospital hematology and oncology services to switch from use of cuffed and tunneled CVCs to PICCs is justified, particularly since PICCs are more vulnerable to thrombosis and dislodgment, and are less useful for drawing blood specimens. Moreover, PICCs are not advisable in patients with renal failure and impending need for dialysis, in whom preservation of upper-extremity veins is needed for fistula or graft implantation.
外周静脉穿刺中心静脉导管(PICC)目前在当代医疗保健中广泛用于中长期静脉通路,特别是在住院环境中,它们越来越多地取代了经皮插入颈内静脉、锁骨下静脉或股静脉的传统中心静脉导管(CVC)。关于住院患者使用PICC发生PICC相关血流感染(BSI)风险的数据有限。
确定住院患者发生PICC相关BSI的风险。
前瞻性队列研究,使用两项评估洗必泰浸渍海绵敷料和洗必泰用于皮肤消毒效果的随机试验数据。
对1998年至2000年期间两项随机试验中经肘前静脉插入的PICC进行前瞻性研究;大多数患者在重症监护病房(ICU)。通过对拔除PICC时定植于其上的分离株与血培养分离株进行限制性片段DNA亚型分析,证实每例PICC相关BSI。
总体而言,115例患者置入了251根PICC。平均置管时间为11.3天(总计2832个PICC置管日);42%的患者曾在ICU,62%的患者留置导尿管,49%的患者接受过机械通气。确定了6例PICC相关BSI(2.4%),4例为凝固酶阴性葡萄球菌,1例为金黄色葡萄球菌,1例为肺炎克雷伯菌,发生率为每1000个导管日2.1例。
这项前瞻性研究表明,高危住院患者使用的PICC与导管相关BSI发生率与颈内静脉或锁骨下静脉置入的传统CVC相似(每1000个导管日2至5例),远高于仅在门诊使用的PICC(每1000个导管日约0.4例),也高于带袖套和隧道式的希克曼样CVC(每1000个导管日约1例)。需要对需要中心静脉通路的住院患者进行PICC与传统CVC的随机试验。我们的数据提出了一个问题,即在许多医院血液学和肿瘤学服务中,从使用带袖套和隧道式CVC转向使用PICC的趋势是否合理,特别是因为PICC更容易发生血栓形成和移位,且在采集血标本方面作用较小。此外,对于肾衰竭且即将需要透析的患者,PICC并不适用,因为这类患者需要保留上肢静脉用于动静脉内瘘或移植物植入。